Brooks Laboratories FY26: A ₹24.58 Cr Profit Where the Pharma Business Made ₹7 Cr of It

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

After five straight years of losses, Brooks Laboratories closed FY26 with a net profit of ₹24.58 crore against a ₹9.97 crore loss the year before. The EPS line flipped from ₹-3.38 to ₹8.34. On the face of it, a clean turnaround.

The detail underneath complicates the headline. Operating profit for the year was about ₹7 crore on sales of ₹85.74 crore — the first positive operating figure since FY21, but a small one. Sitting beside it is Other Income of ₹19.95 crore, of which ₹18.78 crore is Brooks’s share of profit from its jointly controlled entity, Brooks Steriscience Limited. So the operating pharma business contributed roughly ₹7 crore; the associate stake contributed most of the rest.

Revenue grew 3.85%, from ₹82.56 crore to ₹85.74 crore. ROCE swung to 21.5% from negative territory. The market currently pays about 8.4x earnings here, against a peer median of 34x — a gap that exists partly because the earnings doing the dividing arrived through an associate rather than the factory.

A profit can be entirely real and still tell you almost nothing about the operation that bears the company’s name. The rest of this entry separates the two. Where did ₹24.58 crore actually come from?

2. Introduction

Incorporated in 2002, Brooks Laboratories is a contract manufacturer of pharmaceutical formulations, run from a plant at Baddi in Himachal Pradesh. The range covers liquid injection vials, dry powder injections, carbapenem injectables, tablets and oral suspensions, with applications across antibacterial, antibiotic, anti-gastric, anti-malarial and life-saving therapeutic segments. Around 90% of revenue comes from the domestic market, with exports to Afghanistan, Malaysia, Dubai, Benin and Congo; roughly 20% of revenue is sold under the company’s own brand.

The recent history runs through one structural fact. A loss-making Vadodara unit was transferred into joint venture Brooks Steriscience Limited on a slump-exchange basis in March 2021, after which Brooks turned profitable in FY22. FY23 then slid back into a ₹20.89 crore loss. The years since have been a slow climb back toward operating breakeven.

FY26 also carried a set of corporate events: a CEO appointment, an abandoned diversification plan, an upgraded credit rating, and — after year-end — a partial sale of the very Steriscience stake that now drives the consolidated profit. Section 6 takes those one at a time.

A reminder before the numbers: figures here are consolidated, in ₹ crore, and consolidation is the whole point at this company — it is the line that pulls the associate’s profit onto Brooks’s page.

3. Business Model: WTF Do They Even Do?

Brooks makes drugs for other people. It is a contract and loan-licence manufacturer, plus a modest own-brand and trading operation, reporting through two segments: Manufacturing and Trading.

The segment split is almost comic in its lopsidedness. Manufacturing booked ₹82.87 crore of FY26 revenue and a ₹6.94 crore segment result. Trading booked ₹2.87 crore of revenue and lost ₹0.06 crore — a business that, at this scale, mostly exists to remind the manufacturing segment how good it has things.

The installed capacity is genuinely large for a company this size: 2.30 crore liquid injection vials, 13.82 crore tablets, 2.01 crore dry-syrup units, 5.76 crore ampoules, 2.30 crore eye/ear drop units and 5.19 crore dry-powder injection units a year. The constraint has never been the machinery. It has been filling it profitably — sales have compounded at just 2.11% over five years while the plant stood ready for much more.

That is the recurring tension in a tender-and-contract pharma model: you win volume by being the cheapest credible bidder, which means margin lives or dies on raw-material costs you don’t control. FY23’s losses came down to API price volatility; the years since have been about clawing input costs back. The factory is fine. The economics of who gets to keep the value are the question.

A plant running below its profitable capacity is the most expensive kind of idle — it costs depreciation every year while you wait for the order book to grow into it.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Three of these four lines flipped sign in a single year, which would be a remarkable operating story if the PAT line were an operating line. It isn’t. Operating profit moved from roughly ₹-8 crore to ₹+7 crore — a real ₹15 crore swing at the level the factory controls. The remaining distance to ₹24.58 crore of PAT is carried by Other Income, dominated by the ₹18.78 crore associate profit share.

The audited consolidated statement makes the mechanics explicit: standalone profit before tax was ₹5.80 crore, and the share of profit from the jointly controlled entity added ₹18.78 crore to reach a consolidated ₹24.58 crore. The audit opinion was unmodified.

On the concall / rating side: CARE Ratings, in its November 2025 note, expected FY26 total operating income of about ₹100 crore. Reported FY26 sales came in at ₹85.74 crore — short of that figure by roughly ₹14 crore.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays about 8.4x earnings here, against a peer median of 34x. ROE reads 22.3% for the latest year, sitting above a five-year average of -8.8% — the average is negative because four of the last five years were loss-making, which is also why no meaningful historical P/E or P/B exists to print. ROCE of 21.5% sits above the peer median of 15.14%.

What the market appears to be weighing is the composition of those returns. The current ROE and the single-digit multiple both rest on a profit that is mostly associate-derived rather than operating, and the company’s own sales growth has been 2.11% over five years. The low multiple relative to peers describes earnings the market does not yet treat as recurring operating earnings — the per-year history that would settle that question doesn’t exist, because the operating profit only just turned positive.

The factual observation on market expectations: peers in this set are priced at four times Brooks’s multiple, on operating track records that span years rather than one turnaround.

6. What’s Cooking

The dump records real events, and there are several:

The board approved, on 19 June 2026, the sale of 51,220 Brooks Steriscience shares to Steriscience Specialties Private Limited at ₹20,760 per share — about ₹106.33 crore — cutting Brooks’s holding from 49% to 32.67%. The company states proceeds will go toward expansion, capacity and general corporate purposes. This is the same Steriscience stake whose profit share built most of FY26’s consolidated PAT.

On 29 May 2026, Prashant Rathi was appointed CEO effective 1 June, retaining his CFO role. A composite merger of Brooks Steriscience into OneSource Speciality Pharma — which CARE had described in November 2025 — was, per a 14 May 2026 disclosure, not pursued in its current form. On 30 January 2026, the ITAT Chandigarh dismissed Brooks’s tax appeals for AYs 2012-13, 2014-15 and 2016-17; the company cited no material financial impact. And in November 2025, CARE upgraded the long-term rating to CARE BB; Stable from CARE BB-; Stable.

Five real events, no manufactured drama. The single thread worth holding: the asset that delivered the profit is being partially sold the year after it delivered it.

7. Balance Sheet

Assets equal liabilities in every column.

• Net worth nearly doubled across two years, from ₹65.59 crore to ₹122.66 crore — driven by an FY25 equity raise and FY26’s retained profit, not by borrowing.
• Borrowings crept to ₹8.52 crore against cash and bank balances of ₹7.55 crore, leaving net debt of roughly ₹1 crore. On the printed balance sheet, this is close to a debt-free company.
• The off-balance-sheet picture is heavier: contingent liabilities of ₹75.7 crore, and a corporate guarantee of ₹68.62 crore extended for Brooks Steriscience’s borrowings.

A balance sheet can be debt-free on the page and still be carrying someone else’s debt in the footnotes — the ₹68.62 crore guarantee is the kind of obligation that doesn’t show up until the day it does.

8. Cash Flow: Sab Number Game Hai

FY25 is the year the story is told in. A ₹45.14 crore investing outflow — largely the ₹43.66 crore poured into the joint venture — was funded almost exactly by ₹42.43 crore of financing inflow from the equity raise. Money came in the front door and left through the side door into Steriscience. FY26 is calmer: operating cash flow of ₹9.29 crore finally exceeded operating profit, and the company barely touched financing.

Operating cash turning positive and rising is the line that distinguishes a genuine recovery from an accounting one — here it moved from ₹-9.80 crore to ₹9.29 crore in two years.

9. Ratios: Sexy or Stressy?

ROE of 22.3% describes a single strong year laid over a three-year average of -1.91% — the equity has had one good shift after several poor ones. ROCE at 21.5% sits well above the company’s own recent history of negative returns through FY25. The PAT margin of 28.7% looks extraordinary for a low-margin contract manufacturer, and it is — it is inflated by the associate profit share running through Other Income, not by the operation, whose OPM is about 8.2%. D/E of 0.07 confirms the company funds itself with equity, not borrowing.

10. P&L Breakdown: Show Me the Money

The Other Income column is the entry’s whole argument. For two years it sat near ₹1 crore — a rounding error beside operating losses. In FY26 it jumped to ₹19.95 crore, of which ₹18.78 crore is the Steriscience profit share. Anchor on Operating Profit and PAT together and the trajectory reads honestly: the operation crawled from ₹-18 crore to ₹+7 crore of operating profit across three years, a genuine and gradual repair; the headline ₹24.58 crore PAT then arrives mostly from outside that operation.

EPS moved in the same direction as PAT — from ₹-3.38 to ₹8.34 — so the swing is a profit swing, not a share-count artefact. (The share count did rise earlier, via an FY25 preferential issue of 32,10,510 shares at ₹141.50, which is why per-share figures across years sit on a moving base.)

11. Peer Comparison

Brooks is a ₹206 crore company in a peer set measured in lakhs of crores — its quarterly sales are roughly what Sun Pharma books before lunch. The multiple gap is as wide as the size gap inverts it: Brooks trades at about a quarter of the peer median multiple, on a profit base whose largest single component is an associate stake it is now partly selling. The peers carry years of operating earnings; Brooks carries one turnaround year and a footnote.

12. Miscellaneous: Shareholding & Promoters

The promoter group — led by Atul Ranchal and Rajesh Mahajan, each with about two decades in the industry — has steadily reduced its holding from 66.41% in June 2023 to 52.62%, a decline of roughly 13.8 percentage points over three years. On the institutional side, Quant Mutual Fund’s Business Cycle Fund holds 9.90%, the bulk of the 10.38% DII stake. Pledged shares stand at zero.

A promoter group that has trimmed from two-thirds to just over half across three years is making a visible statement of its own about where it is putting its capital — and the direction has been steadily out, not in.

13. Corporate Governance: Angels or Devils?

The auditor, DMKH & Co., issued an unmodified opinion on the FY26 consolidated and standalone results — the cleanest signal on the page. The secretarial compliance report for FY26 was largely clean, with one recorded blemish: a ₹5,900 penalty paid to BSE and NSE for appointing a qualified compliance officer on 26 December 2024, five days after the prescribed deadline. A ₹5,900 fine on a ₹206 crore company is the corporate-governance equivalent of a parking ticket, but it is on the record.

On tax, the ITAT Chandigarh dismissed Brooks’s appeals for three assessment years in January 2026; the company states no material financial impact. The larger items are the contingent liabilities of ₹75.7 crore and the ₹68.62 crore corporate guarantee for the associate’s borrowings. Pledges are nil, related-party transactions of ₹35 crore were placed before the AGM, and a proposed diversification into crypto, digital-treasury and lending businesses was abandoned when the e-Form MGT-14 for the object-clause change was not approved by the Registrar — leaving the company, by its own statement, exclusively in pharmaceuticals.

14. Industry Roast & Macro Context

Contract pharma manufacturing is a sector that has perfected the art of doing essential work for thin reward. The product saves lives; the margin barely survives. Tender-based supply means the buyer holds the whip, raw-material (API) prices swing on forces no formulator controls, and regulatory compliance is a permanent fixed cost that grows but never sells a single extra vial. CARE’s note captures the structural reality plainly: a highly regulated, intensely competitive industry crowded with small and large players, where keeping a plant compliant across geographies is the price of entry, not a moat.

It is an industry where having a large, certified factory is necessary, completely insufficient, and quietly expensive all at once.

15. EduInvesting Verdict

The central fact of Brooks Laboratories in FY26 is that its best year of reported profit and its decision to partly sell the source of that profit arrived in the same twelve months. The factory finally earned a positive ₹7 crore; the associate delivered ₹18.78 crore; and the stake behind that ₹18.78 crore is being trimmed from 49% to 32.67%.

A turnaround at the operating line, sitting beside a profit that mostly came from somewhere the company is heading out of.